Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million
Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs
https://www.globenewswire.com/news-release/2024/11/11/2978617/0/en/23andMe-Announces-Business-Restructuring-to-Streamline-Operations-Reduce-Costs-and-Position-Company-for-the-Future.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.